<i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors
<i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors is a paper indexed in ScholarIQ from OpenAlex.
How many citations does <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors have?
<i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors has 44 citations in the OpenAlex counts ScholarIQ stores.
When was <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors published?
<i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors has 2016 year in the ScholarIQ index.
What is the open-access status of <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors?
<i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors has diamond oa status in the ScholarIQ index.
What is the DOI of <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors?
The DOI for <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors is on the source record.
What is the PMID of <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors?
The PMID for <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors is on the source record.
What is the OpenAlex record for <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors?
The OpenAlex for <i>TACC3</i> overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors is on the source record.